GANX vs. ACB, NGNE, TVRD, BTMD, SLRN, TVGN, CGC, PRQR, NBTX, and YMAB
Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), biote (BTMD), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry.
Gain Therapeutics vs. Its Competitors
Gain Therapeutics (NASDAQ:GANX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.
Gain Therapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
In the previous week, Gain Therapeutics and Gain Therapeutics both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 0.76 beat Aurora Cannabis' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.
12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Gain Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 412.50%. Given Gain Therapeutics' higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than Aurora Cannabis.
Aurora Cannabis has a net margin of 1.32% compared to Gain Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Gain Therapeutics' return on equity.
Aurora Cannabis has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Summary
Aurora Cannabis beats Gain Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Gain Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gain Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GANX) was last updated on 7/8/2025 by MarketBeat.com Staff
